There are 10+ firms vying ro bring a generic glp1 anywhere the patent has expired. How effective these generics will be is yet to be seen.
This might cause a lot of problems because some people are taking glp1 for "my wedding is in 1 month and I gotta reduce 10kg by then"
So Novo Nordisk itself droped the price a LOT in the last weeks, and even after the price drop you can get the first month free at a lower dosage when starting with a higher one.. Like if you got the 5ml prescripted to you would they send firs month of the 2.5ml for free..
Even the propspect of having generics in the market is already making the price drop..
But I suppose they also have to reduce price some or the other day.
In India a few glp1 drugs are launching tomorrow. So I think they already got approval
Food is just another drug.
Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists
Pure profit protection when they make back enough money to fund every one of their drugs off a single patent that they continue to renew for 20 years by slightly modifying the syringe to now have an amazing new innovation like an integrated safety cap, or some other drug-irrelevant bs.
Both Copyright and Patents in the US need 21st century reform to something that is reasonable for the speed of modern technology.
https://pubmed.ncbi.nlm.nih.gov/36495532/
And that mechanism can be tweaked and repeatedly patented.
One of the positive cases for patents on medicines is that they are often chemicals. It's fairly simple to tell whether a chemical is the same or different. "Good fences make good neighbors". You infringe the patent or you don't, and you know that in advance.
But if you want to introduce a similar mechanical device to deliver your definitely patent free generic, now you have to roll the dice that the dozens of patents they've taken out on different delivery mechanism don't affect your approach.